Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.42 |
| ▸ | PIM1 | P11309 | 4/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6257917 | 0.92 | SMN1; SMN2 (0.85) | SMN1; SMN2ALDH1A1KDM4EHSD17B10LMNA | |
| SCHEMBL6264252 | 0.85 | ALDH1A1 (0.73) | SMN1; SMN2ALDH1A1KDM4EHSD17B10SCN5A | |
| SCHEMBL15007056 | 0.80 | SMN1; SMN2 (0.67) | SMN1; SMN2ALDH1A1KDM4EHSD17B10LMNA | |
| SCHEMBL11918906 | 0.73 | KDM4E (0.56) | SMN1; SMN2ALDH1A1KDM4EHSD17B10LMNA | |
| SCHEMBL12540237 | 0.70 | ALDH1A1 (0.53) | SMN1; SMN2ALDH1A1KDM4EHSD17B10SCN5A | |
| SCHEMBL1189278 | 0.69 | ALDH1A1 (0.53) | SMN1; SMN2ALDH1A1KDM4EHSD17B10SCN5A | |
| SCHEMBL15898868 | 0.69 | ALDH1A1 (0.52) | SMN1; SMN2ALDH1A1KDM4EHSD17B10SCN5A | |
| Bromide SCHEMBL1189112 | 0.68 | ALDH1A1 (0.51) | SMN1; SMN2ALDH1A1KDM4EHSD17B10SCN5A | |
| SCHEMBL15013681 | 0.68 | SMN1; SMN2 (0.51) | SMN1; SMN2ALDH1A1KDM4EHSD17B10LMNA | |
| SCHEMBL13757325 | 0.67 | KDM4E (0.57) | SMN1; SMN2ALDH1A1KDM4EHSD17B10LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050113283-A1 | Methods of treating conditions associated with an EDG-4 receptor | MANIV ENERGY CAPITAL | 2005-05-26 | — | — | US | disclosed |
| EP-1513522-A2 | METHODS OF TREATING CONDITIONS ASSOCIATED WITH AN EDG RECEPTOR | SRI INTERNATIONAL (US) | 2005-03-16 | — | — | EP | disclosed |
| WO-2003062392-A2 | METHODS OF TREATING CONDITIONS ASSOCIATED WITH AN EDG RECEPTOR | CERETEK LLC (US) | 2003-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113283-A1 | Methods of treating conditions associated with an EDG-4 receptor | EDNRA, EDNRB, ESRRG | SMN1; SMN2 2732/4885ALDH1A1 2855/4885KDM4E 2621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.